Psyence Biomedical Ltd. Warrant
NASDAQ: PBMWW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jody Aufrichtig
- Employees
- 12
- Headquarters
- Toronto, Canada
- IPO year
- 2024
- Market cap
- $1.7K
- Website
- https://www.psyencebiomed.com
Loading PBMWW…
Loading profile data…Frequently asked questions about PBMWW
What does Psyence Biomedical Ltd. Warrant (PBMWW) do?
Psyence Biomedical Ltd. focuses on developing psychedelic medications derived from botanical psilocybin. The company is also investigating the use of natural psilocybin to alleviate adjustment disorder in patients with incurable cancer who are undergoing palliative care. Its primary product candidate, PEX010, is a capsule containing naturally so...
Where does PBMWW trade?
Psyence Biomedical Ltd. Warrant (PBMWW) trades on the NASDAQ Global Market.
What sector is PBMWW in?
Psyence Biomedical Ltd. Warrant (PBMWW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Psyence Biomedical Ltd. Warrant?
Jody Aufrichtig is the chief executive officer of Psyence Biomedical Ltd. Warrant (PBMWW).
Where is Psyence Biomedical Ltd. Warrant headquartered?
Psyence Biomedical Ltd. Warrant is headquartered in Canada.
Does PBMWW pay a dividend?
Psyence Biomedical Ltd. Warrant (PBMWW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PBMWW go public?
Psyence Biomedical Ltd. Warrant (PBMWW) completed its initial public offering in 2024.